Molecular Partners AG (SWX:MOLN)
Switzerland · Delayed Price · Currency is CHF | Market Cap | 115.91M +4.8% |
| Revenue (ttm) | n/a |
| Net Income | -58.02M |
| EPS | -1.55 |
| Shares Out | 37.51M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 10,711 |
| Open | 3.110 |
| Previous Close | 3.090 |
| Day's Range | 3.040 - 3.180 |
| 52-Week Range | 2.660 - 3.960 |
| Beta | 0.71 |
| Analysts | Buy |
| Price Target | 9.00 (+196.05%) |
| Earnings Date | Aug 25, 2026 |
About Molecular Partners AG
Molecular Partners AG, a clinical-stage biotechnology company, designs and develops designed ankyrin repeat proteins therapeutics for the treatment of oncology diseases in Switzerland. Its product pipeline comprises MP0317, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; MP053, novel tetra-specific T cell-engaging DARPin, which is phase 1 clinical trial for the treatment of acute myeloid leukemia; and MP0712, a 212Pb Radio-DARPin therapy (RDT) candidate targeting the tumor-associated protein delta-like ligand 3 (D... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 2 analysts, the average rating for MOLN stock is "Buy." The 12-month stock price target is CHF 9.00, which is an increase of 196.05% from the latest price.
News
Molecular Partners Holds Presentations at ASCO and SNMMI 2026 on DLL3-Targeting Radio-DARPin MP0712, Now Dosing Patients in Phase 1
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., May 30, 2026 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech ...
Molecular Partners AG Transcript: 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA
DARPins offer a flexible, modular platform for radioligand therapy, with MP0712 showing promising early safety and tumor-targeting data in small cell lung cancer. MP0726 targets mesothelin with a unique approach, and additional pipeline assets are advancing, with key data and disclosures expected over the next 12–18 months.
Molecular Partners to Present at TD Cowen's 7th Annual Oncology Innovation Summit
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., May 26, 2026 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-bu...
Molecular Partners Reports Financial Results and Highlights for Q1 2026, with Clinical Studies Initiated on MP0712 and MP0317
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech ...
Molecular Partners AG Earnings release: Q1 2026
Molecular Partners AG released its Q1 2026 earnings on May 12, 2026, summarizing the period's financial results.
Molecular Partners AG Slides: Corporate presentation
Molecular Partners AG has posted slides in relation to its latest quarterly earnings report, which was published on May 12, 2026.
Molecular Partners to hold oral presentations on DLL3-targeting Radio-DARPin candidate MP0712 at multiple upcoming scientific conferences
ZURICH-SCHLIEREN, Switzerland and Concord, Mass., May 04, 2026 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a novel class of custom-...
Molecular Partners publishes Phase 1 MP0317 data in Nature Cancer demonstrating tumor-localized CD40 activation and tumor microenvironment remodeling
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., May 01, 2026 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech...
Molecular Partners presents three posters at AACR 2026, with new preclinical data for first Switch-DARPin T cell engager MP0632 and DLL3 Radio-DARPin MP0712
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass, April 19, 2026 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a novel class of custom...
Molecular Partners Announces all Board Proposals Approved, Clare Fisher Elected as New Board Member at Annual General Meeting
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., April 14, 2026 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotec...
Molecular Partners Publishes Invitation to Annual General Meeting 2026 and Proposes Clare Fisher for Election to its Board of Directors
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., March 23, 2026 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a novel class of custo...
Molecular Partners Presents New Preclinical Data Highlighting Radio-DARPins' Amenability to Multiple Isotopes
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., March 19, 2026 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a novel class of custo...
Molecular Partners to Hold Three Poster Presentations at AACR 2026
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., March 17, 2026 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a novel class of custo...
Molecular Partners Reports Highlights and Financial Results for Full Year 2025
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., March 12, 2026 (GLOBE NEWSWIRE) -- Zurich-Schlieren, Switzerland and Concord, Mass., March 12, 2026 – Ad hoc announcement pursuant to Art. 53 LR Molec...
Molecular Partners AG Earnings release: Q4 2025
Molecular Partners AG released its Q4 2025 earnings on March 12, 2026, summarizing the period's financial results.
Molecular Partners AG Annual report: Q4 2025
Molecular Partners AG has published its Q4 2025 annual report on March 12, 2026.
Molecular Partners AG Slides: Q4 2025
Molecular Partners AG has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on March 12, 2026.
Molecular Partners AG Transcript: Leerink Global Healthcare Conference 2026
The company is advancing its DARPin-based radiotherapy and T cell engager platforms, prioritizing radiotherapy due to its high ROI and rapid clinical progress. Lead programs target DLL3 and mesothelin, with phase I trials underway and strong early safety and efficacy signals. Cash reserves support operations into 2028.
Molecular Partners Announces Participation in March Investor Conferences and Upcoming 2025 Financial Results
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-b...
Molecular Partners AG Transcript: Study update
MP0712, a DLL3-targeting radiotherapeutic, showed strong tumor uptake and favorable biodistribution in SCLC patients, with healthy organs remaining within safety limits. The phase I/II trial is open, with safety and early efficacy data expected in 2024, and plans for dose escalation and future expansion to other radionuclides and indications.
Molecular Partners AG Press release: Study update
Molecular Partners AG issued a press release on February 2, 2026, disclosing material business information to investors.
Molecular Partners AG Slides: Study update
Molecular Partners AG has posted slides in relation to its latest quarterly earnings report, which was published on February 2, 2026.
Molecular Partners Announces Presentation of First Imaging and Dosimetry Data of DLL3-Targeting Radiotherapy MP0712 in Patients at TWC 2026
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech...
Molecular Partners AG Transcript: 44th Annual J.P. Morgan Healthcare Conference
The presentation highlighted renewed optimism in biotech, with a strategic focus on radiotherapy and the MP0712 program. Early clinical data show promising tumor targeting and safety, with key updates expected throughout the year.
Molecular Partners AG Slides: 44th Annual J.P. Morgan Healthcare Conference
Molecular Partners AG has posted slides in relation to its latest quarterly earnings report, which was published on January 15, 2026.